Hong Kong stock fluctuation | Genscript Biotech (02367) rose nearly 4% during the session. The performance of KeFuMei and KeLiJin during the november 11 shopping festival-related may support the company in achieving its annual profit target.

Jushi Group (02367) rose nearly 4% during trading hours. As of the press time, it increased by 3.88% to HK$50.9, with a transaction value of 73.9355 million Hong Kong dollars.

Zhitong FinanceNov 26 21:26 ET

Sinolink: In 2025, competition in beauty, medical aesthetics, and gold jewelry may continue to be intense. The popularity of trendy products is expected to continue with the resonance of supply and demand sentiment.

Beauty, medical beauty, gold jewelry and other optional consumer sectors are experiencing weakening prosperity, intensifying internal circulation, with emotional consumption leading the market, and the trendy market continuing to expand.

Zhitong FinanceNov 26 21:11 ET

haitong int'l: Taotian brand-driven, TikTok gift box bestsellers november 11 shopping festival-related cosmetics leader multi-platform growth

During the november 11 shopping festival-related, Douyin achieved high growth with an increased share of commodity cards; the contribution of the Taotian platform's GMV exceeded 50%, and brand collaboration created additional growth. The growth momentum of domestic products is strong, with leading brands experiencing multiple bursts of activity.

Zhitong FinanceNov 20 02:46 ET

Here's Why Giant Biogene Holding (HKG:2367) Has Caught The Eye Of Investors

Simply Wall StNov 17 22:04 ET

[Brokerage Focus] CMB International raises target price for Giant Sons (02367) by 6.6%, highlighting strong online growth of two core brands during singles' day sales.

Jingu Financial News | CICC issued research reports stating that during singles' day sales, JuZiBiotech (02367) saw strong growth in online sales of its two core brands KeFuMei and KeLiJin. The online omni-channel GMV of KeFuMei and KeLiJin increased by over 80% and over 150% respectively year-on-year, showing faster growth compared to this year's "618". KeFuMei and KeLiJin experienced explosive growth on the Douyin platform, with year-on-year growth of over 100% and over 500% respectively during singles' day sales. KeFuMei's collagen sticks continued high growth with impressive performance of new products. KeLiJin intensified its new product efforts, rapidly releasing growth potential. The bank believes that the continuously enriched product matrix will drive long-term brand growth.

Jingu Financial NewsNov 14 00:32 ET

CMB International: Maintains a "buy" rating on Genscript Biotech (02367) with a target price of 66.15 Hong Kong dollars.

CMB International remains bullish on the rapid growth of JuZi Biotech's skincare products, expecting collagen injection products to be approved in 1Q25E.

Zhitong FinanceNov 13 20:51 ET